首页> 外文OA文献 >864 Efficacy of Vedolizumab Induction Therapy in Patients With Crohn's Disease Who Have Experienced Tumor Necrosis Factor Antagonist Failure or Are Tumor Necrosis Factor Antagonist Naive

【2h】

864 Efficacy of Vedolizumab Induction Therapy in Patients With Crohn's Disease Who Have Experienced Tumor Necrosis Factor Antagonist Failure or Are Tumor Necrosis Factor Antagonist Naive

机译：864 Vedolizumab诱导治疗患者患有经历肿瘤坏死因子拮抗剂失败的患者患者的疗效，或者是肿瘤坏死因子拮抗剂天真

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Bruce E. Sands; William Sandborn; Paul J. Rutgeerts; Jing Xu; Brihad Abhyankar; Irving Fox;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed [J] . SandsB.E., FeaganB.G., RutgeertsP., Gastroenterology . 2014,第3期

机译：vedolizumab诱导疗法对克罗恩病患者肿瘤坏死因子拮抗剂治疗失败的影响
2. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-alpha Antagonist [J] . Holko Przemyslaw, Kawalec Pawel, Pilc Andrzej PharmacoEconomics . 2018,第7期

机译：肿瘤坏死因子 - α拮抗剂失败后Vedolizumab和Ustekinumab对克罗恩病治疗的成本效果分析
3. Proactive infectious disease approach to dermatologic patients who are taking tumor necrosis factor-alfa antagonists: Part II. Screening for patients on tumor necrosis factor-alfa antagonists [J] . Journal of the American Academy of Dermatology . 2014,第1期

机译：正在服用肿瘤坏死因子-α拮抗剂的皮肤科患者的主动传染病方法：第二部分。筛选肿瘤坏死因子-α拮抗剂的患者
4. Effect of CV6209, A platelet-activating factor antagonist, on shiga toxin-induced tumor necrosis factor-alpha expression in human monocytic cells [C] . Hui-Min Zhang, Tatsuo Yamamoto 7th China-Japan International Congress of Microbiology Shanghai Symposium-2000 4-6 August 2000 Shanghai . 2000

机译：血小板活化因子拮抗剂CV6209对芝加毒素诱导的人单核细胞中肿瘤坏死因子-α表达的影响
5. Biolo?ki Procesi in Napovedovanje Neodzivnosti Na Zaviralce Dejavnika Tumorske Nekroze Pri Crohnovi Bolezni z Integracijo Genomskih Podatkov =Biological processes and predicting non-response to tumor necrosis factor inhibitors in Crohn's disease by integr [D] . Jezernik, Gregor. 2021

机译：通过整合基因组数据=生物学过程和预测携带基因组疾病肿瘤疾病肿瘤坏死因子抑制剂的生物过程和预测性
6. Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist [O] . Przemysław Holko, Paweł Kawalec, Andrzej Pilc -1

机译：Vedolizumab和Ustekinumab治疗肿瘤坏死因子-α拮抗剂失败后克罗恩病的成本-效果分析
7. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed [O] . Sands, Bruce E., Feagan, Brian G., Rutgeerts, Paul, 2014

机译：vedolizumab诱导疗法对克罗恩病患者肿瘤坏死因子拮抗剂治疗失败的影响

864 Efficacy of Vedolizumab Induction Therapy in Patients With Crohn's Disease Who Have Experienced Tumor Necrosis Factor Antagonist Failure or Are Tumor Necrosis Factor Antagonist Naive

著录项

引文网络

相似文献

相关主题

期刊订阅